Expanding the Proteomic Landscape of Venous Thromboembolism: Novel Biomarkers and Causal Insights from Large-Scale Cohort Meta-Analyses

Highlights

Identification of 23 plasma proteins significantly associated with incident venous thromboembolism (VTE) risk, 15 of which are novel to VTE pathophysiology.

Utilization of high-throughput aptamer-based (SomaScan) and antibody-based (Olink) platforms across five major longitudinal cohorts (ARIC, CHS, MESA, HUNT, and UK Biobank).

Mendelian Randomization (MR) analyses provided evidence for potential causal roles of TIMD4, TIMP4, and CST3 in VTE development.

Identified markers shift the focus from traditional coagulation factors toward extracellular matrix regulation, immune-vascular interactions, and vascular senescence.

Background

nVenous thromboembolism (VTE), comprising deep vein thrombosis and pulmonary embolism, remains a major contributor to global cardiovascular morbidity and mortality. Despite decades of research focused on the coagulation cascade and Virchow’s Triad (stasis, endothelial injury, and hypercoagulability), many incident VTE events occur in individuals without traditional risk factors. There is a pressing clinical need to identify novel biomarkers that can better stratify risk and provide insights into the early molecular perturbations leading to thrombus formation. Modern proteomics offers a high-dimensional window into the plasma proteome, allowing for the unbiased discovery of proteins that may serve as early indicators or functional drivers of disease.nn

Key Content

Study Design and Methodological Rigor

nThe study by Tang et al. (2026) represents one of the most comprehensive proteomic investigations into VTE to date. The discovery phase involved a meta-analysis of three prospective U.S. cohorts: the Atherosclerosis Risk in Communities (ARIC) study, the Cardiovascular Health Study (CHS), and the Multi-Ethnic Study of Atherosclerosis (MESA). This was followed by replication in the Norwegian Trøndelag Health (HUNT) study and further external validation using the UK Biobank (UKB) proteomics panel.nnMethodologically, the researchers employed the SomaScan platform to measure approximately 5,000 to 7,000 proteins. By applying Cox proportional hazards regression adjusted for age, sex, and race, the team identified proteins associated with noncancer-related VTE over a follow-up period spanning up to 29 years. The use of the Olink platform for replication in the UK Biobank cohort added significant cross-platform validity to the findings.nn

Discovery of Novel Proteomic Markers

nThe meta-analysis identified 23 proteins associated with VTE risk at a false discovery rate (FDR) < 0.05. Of these, 15 had not been previously linked to VTE in high-throughput studies. Notably, three proteins—TAGLN (Transgelin), SVEP1 (Sushi, von Willebrand factor type A, EGF and pentraxin domain-containing protein 1), and TIMP4 (Tissue inhibitor of metalloproteinases 4)—exceeded the stringent Bonferroni correction threshold in the HUNT replication cohort.nnThese proteins suggest that VTE risk is mediated by processes far beyond simple clotting factor elevations. For instance, SVEP1 is known to be involved in cell adhesion and has been previously linked to residual inflammatory risk in atherosclerosis. Its association with VTE highlights a potential overlap between arterial and venous thrombotic mechanisms.nn

Causal Inference via Mendelian Randomization

nTo move beyond mere association, the investigators utilized Mendelian Randomization (MR), which uses genetic variants as instrumental variables to assess causality. MR analysis of the 15 novel proteins yielded significant evidence for TIMD4 (T-cell immunoglobulin and mucin domain containing 4) and suggestive evidence for TIMP4 and CST3 (Cystatin C).nnInterestingly, the MR findings for TIMP4 and TIMD4 showed an association direction opposite to that observed in the longitudinal plasma analysis. Such discrepancies often point to complex feedback loops or compensatory mechanisms in the body. However, for CST3, the MR and proteomic directions were consistent, reinforcing its status as a robust candidate for a causal driver of venous thrombosis.nn

Biological Pathways and Mechanistic Insights

nThe identified proteins were enriched in pathways involving:n

Extracellular Matrix (ECM) Regulation: Proteins like TIMP4 and SVEP1 suggest that the structural integrity and remodeling of the vessel wall are critical in early VTE pathogenesis.

Immune-Vascular Interactions: The presence of TIMD4, involved in the clearance of apoptotic cells, suggests that impaired efferocytosis or chronic low-grade inflammation may predispose individuals to venous thrombi.

Vascular Senescence: Several markers correlate with aging of the vasculature, potentially explaining why age remains the strongest non-genetic risk factor for VTE.

Expert Commentary

nThe transition from traditional candidate-gene or candidate-protein studies to high-throughput proteomics marks a new era in cardiovascular medicine. This study’s strength lies in its multi-ethnic approach and the use of two different proteomic technologies (aptamer vs. antibody-based), which minimizes the likelihood of platform-specific artifacts. nnThe discovery of SVEP1 and TIMP4 is particularly intriguing from a clinical perspective. These proteins are already under investigation in the context of arterial disease and heart failure; finding them at the center of VTE pathophysiology suggests a more unified “pan-vascular” disease model. However, the discrepancy in the MR results for TIMD4 and TIMP4 serves as a reminder that the plasma concentration of a protein at baseline may reflect a different biological state than the lifelong genetically determined level. nnFrom a health policy and diagnostic standpoint, while these markers are not yet ready for routine clinical use, they provide the foundation for a “proteomic risk score.” Such a score could eventually complement clinical tools like the Wells score or the Geneva score, particularly in identifying individuals who would benefit from extended primary prophylaxis following surgery or during periods of immobility.nn

Conclusion

nThis large-scale proteomic study has significantly expanded our understanding of the molecular precursors of venous thromboembolism. By identifying 15 novel proteins and validating several through genetic causal inference, the research shifts the focus toward the vascular microenvironment and immune regulation. Future research should prioritize functional validation of these proteins in animal models and explore whether these markers can enhance the predictive accuracy of current VTE risk assessment tools in diverse clinical settings.nn

References

Tang W, Li A, Austin TR, et al. Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism. Circulation. 2026 Feb 16. doi: 10.1161/CIRCULATIONAHA.125.074493. PMID: 41693575.

Smith NL, et al. Genetic risk factors for venous thromboembolism in the 21st century. Blood. 2023;141(12):1375-1385.

Ganz P, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. 2016;315(23):2532-2541.